Introduction
============

The incidence of thyroid carcinoma has markedly increased worldwide in the past 4 decades ([@b1-ol-0-0-9850],[@b2-ol-0-0-9850]). Papillary thyroid carcinoma (PTC) represents the most common type of well-differentiated thyroid cancer, accounting for 80--85% of thyroid malignancies ([@b3-ol-0-0-9850]). Patients with PTC have a generally favorable prognosis ([@b2-ol-0-0-9850]); however, a 30-year follow-up study demonstrated that recurrence rates and cancer mortality are high in PTC patients with local tumor invasion and lymph node metastasis (LNM) ([@b4-ol-0-0-9850]). Although the predictive value of several biomarkers for PTC prognosis, including microRNA-451 ([@b5-ol-0-0-9850]), B-Raf proto-oncogene, serine/threonine kinase mutation ([@b6-ol-0-0-9850]) and EH domain-containing 2 ([@b7-ol-0-0-9850]) have been investigated, their efficacy has yet to be validated. To the best of our knowledge, reliable biomarkers able to predict the invasiveness of PTC and prognosis of patients are still lacking.

Matrix metalloproteinases (MMPs) are a family of zinc-dependent extracellular proteases that maintain and remodel tissue architecture. The degradation of basement membranes and of extracellular matrix (ECM) is an essential step in tumor invasion and migration; therefore, MMPs serve an essential role in cancer metastasis ([@b8-ol-0-0-9850],[@b9-ol-0-0-9850]). MMP-9, also known as 92 kDa gelatinase/type IV collagenase, is a prominent MMP that is responsible for the migratory and invasive abilities of diverse types of cancer ([@b10-ol-0-0-9850]--[@b16-ol-0-0-9850]). MMPs are closely involved in the stimulation of angiogenesis, which is essential for tumor growth and progression ([@b17-ol-0-0-9850]). In addition, MMP-9 facilitates the release of tissue-bound fibroblast growth factor (FGF) ([@b18-ol-0-0-9850],[@b19-ol-0-0-9850]) and vascular endothelial growth factor (VEGF), which contribute to tumor growth. Consequently, MMP-9 may be considered a novel biomarker and a potential therapeutic target in human cancer.

Considering its contribution to cancer initiation, tumor growth, angiogenesis and migration, the diagnostic and prognosis capacities of MMP-9 have been assessed in various types of cancer ([@b16-ol-0-0-9850],[@b20-ol-0-0-9850],[@b21-ol-0-0-9850]). Furthermore, the overexpression of MMP-9 in colorectal cancer tissue is associated with tumor invasion, LNM and advanced tumor-node-metastasis (TNM) stage ([@b20-ol-0-0-9850]). In addition, increased expression of MMP-9 is observed in patients with glioma, which is associated with advanced glioma grades and negative survival rates ([@b21-ol-0-0-9850]). Researchers have speculated that MMP-9 overexpression promotes circulating tumor cells to shed into the bloodstream by breaking the basement membrane or digesting ECM ([@b16-ol-0-0-9850]).

As determined by immunohistochemistry (IHC), MMP-9 is involved in the progression and aggressiveness of PTC, although some inconsistencies regarding its predictive capacity have been reported ([@b22-ol-0-0-9850]--[@b24-ol-0-0-9850]). The present study aimed to investigate the expression of MMP-9 in tumors from patients with PTC in comparison with samples obtained from patients with benign thyroid nodules (BTNs). The association between MMP expression and the clinicopathological characteristics of patients with PTC was also analyzed. Eventually, the diagnostic and prognostic value of immunohistochemical MMP-9 expression for PTC was investigated.

Patients and methods
====================

### Study population

A group of patients with PTC was retrospectively reviewed at the First Hospital of Jilin University between January 1, 2012 and June 31, 2014. Furthermore, age- and sex-matched subjects with BTN were recruited as controls. The diagnosis of PTC and BTN was made on a pathological basis. BTN was defined as follows: A lump inside the thyroid, an up and down movement when swallowing, and a biopsy confirming the benign nature of the lump. BTNs included nodular goiter and thyroid adenoma. The inclusion criteria for PTC or BTNs were as follows: i) biopsy-confirmed PTC or BTN; ii) age ranged from 18--70 years old. The exclusion criteria for PTC and BTNs were as follows: i) Anticancer therapy prior to admission, including radiotherapy, chemotherapy and thyroidectomy; ii) severe systemic disorders, including heart failure and malignancies; iii) incomplete or missing test results. The present study was approved by the Ethics Committee of the First Hospital of Jilin University, and all participants provided informed consent prior to participation.

The body mass index (BMI) of each patient was calculated as the weight in kilograms divided by height in meters squared (kg/m^2^). All patients with PCT were graded at the time of diagnosis, according to the 7th edition of the American Joint Committee on Cancer TNM staging system ([@b25-ol-0-0-9850]). Early-stage disease was named as TNM stage I or II, whereas advanced-stage disease was named as stage III or IV.

### Thyroid surgery and follow-up

Bilateral or unilateral central-compartment neck dissection was routinely performed in patients with PTC, followed by total or partial thyroidectomy. In addition, patients underwent lateral neck lymph node dissection when the lateral cervical lymph nodes were suspected to be metastatic, based on explicit clinical and/or imaging findings. The same team of surgeons performed all surgical procedures.

Patients with PTC were followed up every 3 months until December 2017. All patients were monitored for postoperative PTC relapses by ultrasound, computed tomography or chest X-ray, and in combination with biochemical measurements, including serum thyroglobulin (Tg) and Tg antibody (TgAb). Disease status was defined as any evidence of disease, including persistently detectable TgAb, Tg ≥1 ng/ml, and structurally persistent disease or metastasis. Structurally persistent disease was defined as the occurrence of locoregional or distant metastasis, regardless of the Tg level. A recurrence event was defined as the structural evidence of a disease identified following a period of no evidence of disease. Disease-free status was classified as no evidence of disease, as aforementioned. Disease-free survival (DFS) time was defined as the period from initial therapy to any evidence of disease or last follow-up. Survival time without structurally persistent disease/recurrent disease (SPRD) was calculated as the interval from initial treatment to the occurrence of structurally persistent disease, recurrent disease or last follow-up.

### Pathological subtypes by hematoxylin and eosin staining (H&E)

Pathological subtypes of enrolled subjects with PTC were investigated by H&E staining for 20 min at room temperature. The results were visualized by Olympus BX51 microscope (Olympus Corporation, Tokyo, Japan).

### Determination of tissue MMP-9 expression by IHC

Thyroid neoplastic tissues were collected from patients with PTC or BTN during thyroidectomy. Tissue specimens were fixed in 4% paraformaldehyde in TBS at 4°C for 18 h. Paraffin-embedded tissue specimens were sectioned at a thickness of 2.0 µm, followed by deparaffinization in xylene and dehydration in a graded series of ethanol solutions. Antigen retrieval was performed by heating the samples (in rice cooker for 20 min at 95°C) in citrate buffer (pH 6.0), and endogenous peroxidase was blocked with 3% hydrogen peroxide for 10 min at room temperature. Afterwards, the sections were incubated with rabbit polyclonal MMP-9 antibody (cat. no. ab38898; Abcam, Cambridge, MA, USA) at a dilution of 1:250 at 4°C overnight. After washing with PBS, the sections were incubated with horseradish peroxidase-labeled goat anti-rabbit immunoglobulin (cat. no. ab6721; Abcam) at a dilution of 1:1,000 at 37°C for 30 min, and the reaction was visualized using 3,3′-diaminobenzidine. Eventually, the specimens were counterstained with Mayer\'s hematoxylin at room temperature for 1 min. The images were photographed using an Olympus BX51 microscope with an Olympus DP-21 digital camera image system (Olympus Corporation). The primary antibody was replaced with non-immune rabbit serum (cat. no. AR0010; Boster, Wuhan, Hubei, China) which served as the negative control.

All samples were blindly inspected by two independent pathologists. Positive immunostaining was visualized as brown granules contained in the cytoplasm. The immunostaining of MMP-9 was scored on the scale of semi-quantitative assessment by evaluating the intensity and percentage of positively stained cells. The intensity of MMP-9 cytoplasmic staining was scored as follows: 0, none; 1, weak; 2, moderate; and 3, strong. The percentage scores were assigned, as follows: 1, ≤25%; 2, 26--50%; 3, 51--75%; and 4, \>75%. These scores were multiplied to arrive at a final score ranging between 0 and 12.

### Statistical analysis

SPSS software (version 18.0; SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. Data were presented as the means ± standard deviation when data were normally distributed and the results were compared using independent student\'s t-test. Data expressed as median and interquartile ranges (IQRs) (25th percentile and 75th percentile) were compared using a Mann-Whitney nonparametric test. Categorical data were expressed as the number of patients and percentages, and the proportions were compared using χ^2^ test.

Receiver operating characteristic (ROC) curves were designed to estimate the diagnostic and prognostic value of MMP-9 in tissues, in terms of sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). The optimal cutoff values of tissue MMP-9 were identified according to the Youden index ([@b26-ol-0-0-9850]). The survival curves were plotted using the Kaplan-Meier method, and compared using log-rank test. Univariate Cox proportional hazard analysis was conducted to determine the risks of disease status and SPRD. Variables with significance (P\<0.05) in univariate analyses were entered into the multivariable phase. Odds ratios (OR) and their 95% confidence intervals (CIs) were calculated to assess the independent contribution of each identified risk factor. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinicopathological characteristics of subjects

In the present study, 112 patients with PTC and 42 control subjects with BTN were included and separated into two groups. There was no significant difference in age between patients with PTC (45.77±10.03 years) and controls (47.36±10.95 years old) (P\>0.05). In addition, there were no significant differences in sex and proportion of subjects who were ≥45 years old between these two groups (P\>0.05). Numerous pathological subtypes of PTC were identified, including 96 cases of classical PTC, nine follicular variants of PTC, three tall cell variants, three diffuse sclerosing variants and one Warthin variant ([Fig. 1A-E](#f1-ol-0-0-9850){ref-type="fig"}). The clinicopathological characteristics of these subjects are presented in [Table I](#tI-ol-0-0-9850){ref-type="table"}.

### Diagnostic accuracy of MMP-9 for distinguishing PTC

MMP-9 was overexpressed in samples obtained from patients with PTC, when compared with control subjects with BTN ([Fig. 2A-D](#f2-ol-0-0-9850){ref-type="fig"}). Furthermore, patients with PTC had a significantly higher IHC score of MMP-9 (median, 4.0; IQR, 2.0--8.0), when compared with control subjects (median, 1.0; IQR, 0.0--1.0) (P\<0.001, [Fig. 2E](#f2-ol-0-0-9850){ref-type="fig"}).

The ROC curve for distinguishing PTC from BTN is presented in [Fig. 3](#f3-ol-0-0-9850){ref-type="fig"}. MMP-9 scores yielded an area under the curve (AUC) of 0.842 (95% CI, 0.776--0.908), with a sensitivity and specificity of 81.3 and 85.7%, respectively, at a cutoff value of 2.0 points ([Fig. 3](#f3-ol-0-0-9850){ref-type="fig"}). Furthermore, the PPV was 93.8%, whereas the NPV was 63.2%. In addition, the positive likelihood ratio was 5.690, whereas the negative likelihood ratio was 0.218.

### MMP-9 IHC expression in PTC with different invasive characteristics

Mann-Whitney test analysis was conducted to explore the association between MMP-9 and the invasive characteristics of PTC. The IHC expression of MMP-9 was greater if patients had central LNM (CLNM), lateral LNM (LLNM) or an advanced TNM stage (III+IV) (all P\<0.05; [Table II](#tII-ol-0-0-9850){ref-type="table"}). There was no difference in IHC MMP-9 expression in the presence or absence of capsule invasion, multifocality, extrathyroidal invasion, vascular invasion and distant metastasis ([Table II](#tII-ol-0-0-9850){ref-type="table"}).

### Prognostic accuracy of MMP-9 for predicting disease status and SPRD

During the follow-up, patients with a disease status had a significantly higher MMP-9 score (median: 8, IQR: 6.0--9.0) than patients with a disease-free status (median: 3.0, IQR: 2.0--4.0; P\<0.001). At a cutoff value of 6.0 points, MMP-9 yielded an AUC of 0.811 (95% CI, 0.706--0.917), a sensitivity of 88.0% and a specificity of 78.2% for predicting disease-free status ([Fig. 4A](#f4-ol-0-0-9850){ref-type="fig"}).

Patients with SPRD had a significantly higher MMP-9 score (median: 9.0; IQR: 7.0--10.5) than patients without SPRD (median: 4.0; IQR: 2.0--6.0) (P=0.010). Furthermore, when MMP-9 was employed to predict SPRD, an AUC of 0.806 (95% CI, 0.620--0.992) was obtained at a cutoff value of 8.0 points, with a sensitivity and specificity of 77.8 and 76.7%, respectively ([Fig. 4B](#f4-ol-0-0-9850){ref-type="fig"}).

### Risk factors of disease status and SPRD

A univariate logistic regression analysis was performed to identify potential risk factors for predicting disease status. An age of ≥45 years old, a tumor size of \>2 cm, and the presence of CLNM, LLNM, vascular invasion, advanced TNM stage and MMP-9 ≥6 points were identified as risk factors for the development of the disease status (all P\<0.05). In the multivariate model, a tumor size \>2 cm (OR, 3.011; 95% CI, 1.119--8.097; P=0.029) and MMP-9 ≥6 points (OR, 12.210, 95% CI, 3.404--43.798; P\<0.001) were both independent risk factors for disease status in patients with PTC ([Table III](#tIII-ol-0-0-9850){ref-type="table"}).

By univariate Cox regression analysis, a tumor size \>2 cm, capsule invasion, CLNM, LLNM, extrathyroidal invasion, vascular invasion, distant metastasis, advanced TNM stage and an MMP-9 score of ≥8 points were risk factors for SPRD (all P\<0.05). Furthermore, multivariate analysis was performed to evaluate these univariate predictors, and the results revealed that vascular invasion (OR, 17.258; 95% CI, 2.434--122.345; P=0.004) and an MMP-9 score of ≥8 points (OR, 15.329; 95% CI, 1.368--171.717; P=0.027) were independent risk factors for SPRD ([Table III](#tIII-ol-0-0-9850){ref-type="table"}).

### Clinical outcomes stratified by MMP-9 scores

DFS time was shorter in PTC patients with an MMP-9 score of ≥6 points (31.46±11.43 months), when compared to patients with an MMP-9 score of \<6 points (41.11±4.37 months) (P\<0.001). Similarly, PTC patients with an MMP-9 score of ≥8 points had shorter survival time without SPRD (39.6±5.42 months), when compared with patients with an MMP-9 score of \<8 points (41.70±2.34 months) (P=0.001). The Kaplan-Meier curves of survival demonstrated that patients with an MMP-9 score of ≥6 points had lower cumulative DFS rates, when compared to patients with a score of \<6 points (P\<0.001). Furthermore, patients with an MMP-9 score of ≥8 points had a lower cumulative rate of survival without SPRD, when compared to patients with a score of \<8 points (P\<0.001, [Fig. 5](#f5-ol-0-0-9850){ref-type="fig"}).

Discussion
==========

To the best of our knowledge, only a small number of studies regarding MMP-9 in thyroid tumorigenesis have been conducted, in comparison with tumors from other organs, including breast, ovarian, liver, lung and colon cancer, in which MMP-9 expression has already been extensively studied ([@b27-ol-0-0-9850]--[@b31-ol-0-0-9850]). In the present study, the IHC results revealed that MMP-9 expression was significantly higher in PTC tissues than in BTN specimens. In addition, the MMP-9 staining score was greater in the presence of CLNM, LLNM or in the case of advanced TNM stage. Furthermore, the MMP-9 score yielded good sensitivity and specificity for PTC diagnosis and prognostic prediction. A MMP-9 score of ≥6 and ≥8 indicated shortened DFS and survival without SPRD, respectively.

MMPs have essential roles in various biological functions, including cell proliferation, differentiation, ECM degradation and remodeling, angiogenesis and cell migration. Furthermore, the expression and activity of MMP-9 are elevated in numerous types of human cancer ([@b32-ol-0-0-9850]--[@b34-ol-0-0-9850]). In addition, the IHC positive staining of MMP-9 has been reported in 57.0--92.4% of patients with PTC ([@b3-ol-0-0-9850],[@b24-ol-0-0-9850]). In the present study, MMP-9 was expressed at low or almost undetectable levels in BTN specimens (median: 1.0; IQR: 0.0--1.0). Conversely, overexpression of MMP-9 (median: 4.0; IQR: 2.0--8.0) was detected in PTC tissues, and was associated with tumor malignancy. The majority of MMPs are secreted in an inactive form, and can be proteolytically activated by extracellular proteinase, which is critically implicated in carcinogenesis ([@b35-ol-0-0-9850]). The present findings revealed that the MMP-9 IHC score may be useful for the differential diagnosis of PTC from BTN, with a sensitivity and specificity of 81.3 and 85.7%, respectively, and at a cutoff value of 2.0 points. Consistently, Meng *et al* demonstrated that the immunohistochemical staining of MMP-9 yields a sensitivity and specificity of 92.4 and 80%, respectively, for PTC diagnosis from BTN ([@b24-ol-0-0-9850]), thus suggesting a role for MMP-9 in PTC diagnosis. In addition, vasculature is important for tumor size and growth; if the tumor vasculature is not developed, tumors are restricted in size within a tissue-diffusion distance of 0.2--2.0 mm ([@b36-ol-0-0-9850]). MMP-9 has been demonstrated to participate in angiogenesis, as a result, MMP-9 overexpression is likely to be associated with a larger tumor size and is the dependent risk factor for disease status and SPRD ([@b23-ol-0-0-9850],[@b37-ol-0-0-9850]). Above all, MMP-9 is associated with the prognosis of PTC. MMP-9 has been demonstrated to participate in the switch from vascular quiescence to angiogenesis, which is a crucial process required for persistent tumor growth ([@b38-ol-0-0-9850]). The MMP-dependent release of growth factors, including VEGF and FGF, stimulates the progressive growth of tumor cells ([@b39-ol-0-0-9850]). This may explain the present finding that stronger MMP-9 immunostaining was likely to be associated with a larger tumor size (\>2 cm). Furthermore, tumor size (\>2 cm) was dependent predictor for disease status and SPRD, indicating that MMP-9 was correlated with the prognosis of PTC.

Invasion and metastasis substantially contribute to cancer-associated mortality. The disruption of basement membranes is a crucial step in the process of cancer invasion to surrounding tissues and of metastasis to distant organs. The role of MMP-9 is to degrade type IV collagen, which is the main structural component of the basement membrane, and is of particular importance in tumor cell migration ([@b40-ol-0-0-9850]). MMP-9-mediated tumor angiogenesis creates a microenvironment favorable to tumor cell invasion by promoting gas exchange and supplying nutrients ([@b41-ol-0-0-9850]). Furthermore, MMP-9 expression has been reported to be associated with microvessel density in colorectal carcinoma ([@b42-ol-0-0-9850]). In addition, MMP-9 is an essential mediator of epithelial-mesenchymal transition, which is a key step in tumor progression and metastasis ([@b43-ol-0-0-9850]). The association between MMP-9 overexpression and the invasiveness of cancer has been reported in numerous studies ([@b32-ol-0-0-9850],[@b44-ol-0-0-9850]--[@b47-ol-0-0-9850]). In patients with PTC, positive MMP-9 staining is correlated with lymphatic spreading and the degree of tumor infiltration ([@b3-ol-0-0-9850]). Consistent with these findings, the IHC score of MMP-9 was greater in the presence of CLNM, LLNM or advanced TNM stage, indicating that MMP-9 may be used as a predictive biomarker of aggressive PTC behaviors.

The association between MMP-9 expression and malignant neoplasms has garnered much interest, and MMP-9 may be considered a predictor of patient prognosis. It has been reported that elevated MMP-9 expression, as an independent risk factor, is associated with advanced tumor stage and shortened survival in various types of cancer ([@b47-ol-0-0-9850],[@b48-ol-0-0-9850]). In the present study, MMP-9 expression in PTC samples was revealed to represent an independent risk factor for predicting the presence of disease and SPRD following thyroidectomy. Subsequently, high MMP-9 expression was associated with shortened DFS and survival without SPRD in patients with PTC. These results are consistent with a previous study, which reported that MMP-9 is an independent prognostic factor for predicting the worse outcome in patients with PTC following radiofrequency ablation ([@b49-ol-0-0-9850]). In addition, Lin *et al* revealed that median event-free survival was shorter in patients with T-cell acute lymphoblastic leukemia with the CT+TT genotype of MMP-9-1562C\>T, when compared to patients with the CC genotype, suggesting that MMP-9 genetic polymorphism may affect tumor progression and prognosis ([@b50-ol-0-0-9850]). Therefore, the genetic characteristics of MMP-9 and its association with PTC prognosis require further investigation.

The present study differs from previous studies in many ways. To the best of our knowledge, it is the first to carefully assess the diagnostic and prognostic values of MMP-9 immunostaining in patients with PTC and after thyroidectomy. PTC is a more common malignancy in women than in men ([@b51-ol-0-0-9850]); however, male patients with PTC are common in China ([@b52-ol-0-0-9850]). The sex and age were well matched between the BTN group and PTC group, in order to minimize any influences caused by age and sex. In addition, the relationships between MMP-9 and SPRD, and survival without SPRD, were examined, which has rarely been reported in previous studies investigating the predictive role of MMP-9 in PTC prognosis. Finally, previous studies have focused on other proteins, and MMP-9 has only been examined with regards to a few aspects of PTC prognosis ([@b1-ol-0-0-9850],[@b3-ol-0-0-9850],[@b22-ol-0-0-9850],[@b23-ol-0-0-9850]). The present study systematically analyzed the diagnostic and prognostic roles of immunohistochemical MMP-9 in patients with PTC, and identified it as an independent risk factor for disease status and survival. Consequently, the present study may provide detailed evidence for deciding the usefulness of MMP-9 in PTC prediction.

The present study presented numerous limitations. Firstly, this study was a single-center, retrospective cohort analysis with a relatively small sample size. In addition, a longer follow-up period is required to further analyze the relationship between alterations in MMP-9 and the prognosis of patients. Secondly, IHC staining is only a semi-quantitative method for testing MMP-9 protein levels. Quantitative measurements of MMP-9 expression levels and protein activation should be conducted to validate these findings. Thirdly, selection bias at the time of study enrollment may have occurred. Notably, some patients with small PTC lesions or BTNs who refused dissection were not recruited in the study. Finally, although there were five subtypes of PTC in the present study, the number of patients with each of them was very small; therefore, all PTC subtypes were added and analyzed as a whole.

In conclusion, the present study demonstrated that immunohistochemical MMP-9 expression was markedly increased in PTC. In addition, elevated MMP-9 expression was associated with central lymph node metastasis, lateral lymph node metastasis, advanced TNM stage and shortened patient survival. Therefore, the assessment of MMP-9 expression in thyroid carcinoma samples may represent a novel tool for PTC diagnosis and prognostic prediction.
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![Pathological subtypes of PTC of the enrolled patients (hematoxylin and eosin staining; magnification, ×200). (A) Classical PTC; (B) follicular variant of PTC; (C) tall cell variant; (D) diffuse sclerosing variant; (E) Warthin variant. PTC, papillary thyroid carcinoma.](ol-17-02-2308-g00){#f1-ol-0-0-9850}

![Immunohistochemical expression levels of MMP-9. MMP-9 immunostaining was performed in tumors obtained from patients with PTC, and was compared with specimens obtained from patients with BTN. Positive staining was defined as brown-yellow particles or tan-brown particles in the cytoplasm (magnification, ×100). (A) PTC with negative staining (score 0); (B) BTN with negative staining (score 0); (C) PTC with positive staining (score 12); (D) BTN with positive staining (score 12). (E) Immunostaining of MMP-9 was scored on the scale of semi-quantitative assessment by evaluating the intensity and percentage of positive cells. The black central horizontal lines indicate the median, and the error bars (upper and lower horizontal lines) represent the 75th percentile and 25th percentile, respectively, \*\*P\<0.001. Data were analyzed using Mann-Whitney nonparametric test. BTN, benign thyroid tumors; IHC, immunohistochemistry; MMP-9, matrix metalloproteinase-9; PTC, papillary thyroid carcinoma.](ol-17-02-2308-g01){#f2-ol-0-0-9850}

![Receiver operating characteristic curve of immunohistochemical matrix metalloproteinase-9 staining for the diagnosis of papillary thyroid carcinoma.](ol-17-02-2308-g02){#f3-ol-0-0-9850}

![Receiver operating characteristic curves of the immunohistochemical matrix metalloproteinase-9 staining for predicting the prognosis of patients with papillary thyroid carcinoma. (A) Disease-free status; (B) structurally persistent/recurrent disease.](ol-17-02-2308-g03){#f4-ol-0-0-9850}

![Survival curves of patients with papillary thyroid carcinoma by MMP-9 stratification. (A) Cumulative disease-free survival rate for patients with MMP-9 ≥6 points vs. \<6 points. (B) Cumulative survival rate without SPRD for patients with MMP-9 ≥8 points vs. \<8 points. MMP-9, matrix metalloproteinase-9; SPRD, structurally persistent/recurrent disease.](ol-17-02-2308-g04){#f5-ol-0-0-9850}

###### 

Clinicopathological characteristics of patients, n (%).

  Characteristic            PTC (n=112)   BTN (n=42)   P-valuea
  ------------------------- ------------- ------------ ----------
  Age                                                  0.187
    \<45 years old          56 (50.0)     16 (38.1)    
    ≥45 years old           56 (50.0)     26 (61.9)    
  Sex                                                  0.821
    Female                  95 (84.8)     35 (83.3)    
    Male                    17 (15.2)       7 (16.7)   
  Tumor size                                           
    ≤2 cm                   81 (72.3)                  
    \>2 cm                  31 (27.7)                  
  Capsule invasion                                     
    No                      56 (50.0)                  
    Yes                     56 (50.0)                  
  Multifocality                                        
    Unifocal                69 (61.6)                  
    Multifocal              43 (38.4)                  
  Nodal status                                         
    N0                      49 (43.8)                  
    N1a                     42 (37.5)                  
    N1b                     21 (18.7)                  
  Extrathyroidal invasion                              
    Negative                78 (69.6)                  
    Microscopic             25 (22.3)                  
    Macroscopic             9 (8.0)                    
  Vascular invasion                                    
    No                      107 (95.5)                 
    Yes                     5 (4.5)                    
  Distant metastasis                                   
    No                      109 (97.3)                 
    Yes                     3 (2.7)                    
  TNM stage                                            
    I+II                    77 (68.8)                  
    III+IV                  35 (31.3)                  

BTN, benign thyroid nodule; PTC, papillary thyroid carcinoma; TNM, tumor-node-metastasis. aAnalyzed by χ2 test.

###### 

MMP-9 immunohistochemistry expression differences in the groups stratified according to clinicopathological characteristics.

  Variable                                     MMP-9 scorea                        P-valueb
  -------------------------------------------- ----------------------------------- -------------
  Tumor size (\>2 cm vs. ≤2 cm)                6.0 (3.0--9.0) vs. 4.0 (2.0--6.0)   0.053
  Capsule invasion (yes vs. no)                4.0 (2.0--9.0) vs. 3.0 (2.0--6.0)   0.090
  Multifocality (yes vs. no)                   4.0 (1.0--8.0) vs. 4.0 (3.0--8.0)   0.499
  Central lymph node metastasis (yes vs. no)   7.0 (3.0--9.0) vs. 3.0 (2.0--4.0)   **0.002**
  Lateral lymph node metastasis (yes vs. no)   8.0 (5.0--9.0) vs. 3.0 (2.0--4.0)   **\<0.001**
  Extrathyroidal invasion (yes vs. no)         5.0 (3.0--9.0) vs. 4.0 (2.0--6.0)   0.065
  Vascular invasion (yes vs. no)               6.0 (1.0--9.0) vs. 4.0 (2.0--8.0)   0.691
  Distant metastasis (yes vs. no)              3.0 (2.0--6.0) vs. 4.0 (2.0--8.0)   0.721
  TNM stage (III+IV vs. I+II)                  8.0 (3.0--9.0) vs. 3.0 (2.0--6.0)   **0.004**

MMP-9, matrix metalloproteinase-9; TNM, tumor-node-metastasis. aData are presented as the median (25th percentile and 75th percentile). bAnalyzed by Mann-Whitney test. Bold indicates a significant difference.

###### 

Risk factors of disease status and SPRD in patients with PTC, as determined by Cox regression model.

  A, Disease status                                                                                                        
  ---------------------------------------- ------------------------- --------------------------- ------------------------- -------------
  Age (≥45 years old vs. \<45 years old)   4.528 (1.698--12.072)     **0.003**                   2.269 (0.677--7.600)      0.184
  Sex (male vs. female)                    1.511 (0.567--4.027)      0.409                                                 
  BMI (≥25 kg/m2 vs. \<25 kg/m2)           1.731(0.765--3.918)       0.188                                                 
  Tumor size (\>2 cm vs. ≤2 cm)            3.353 (1.528--7.358)      **0.003**                   3.011 (1.119--8.097)      **0.029**
  Capsule invasion (yes vs. no)            1.583 (0.711--3.524)      0.261                                                 
  Multifocality (yes vs. no)               1.364 (0.619--3.005)      0.441                                                 
  CLNM (yes vs. no)                        3.915 (1.688--9.082)      **0.001**                   1.990 (0.729--5.430)      0.179
  LLNM (yes vs. no)                        3.932 (1.780--8.688)      **0.001**                   0.730 (0.256--2.085)      0.557
  Extrathyroidal invasion (yes vs. no)     2.041 (0.916--4.545)      0.081                                                 
  Vascular invasion (yes vs. no)           3.446 (1.029--11.456)     **0.045**                   2.384 (0.655--8.678)      0.188
  Distant metastasis (yes vs. no)          3.354 (0.788--14.273)     0.101                                                 
  TNM stage (III+IV vs. I+II)              2.632 (1.200--5.773)      **0.016**                   0.465 (0.151--1.431)      0.182
  MMP-9 score (≥6 points vs. \<6 points)   16.665 (4.975--55.826)    **\<0.001**                 12.210 (3.404--43.798)    **\<0.001**
                                                                                                                           
  **B, SPRD**                                                                                                              
                                                                                                                           
                                           **Univariate analysis**   **Multivariate analysis**                             
                                                                                                                           
  **Characteristic**                       **OR (95% CI)**           **P-value**                 **OR (95% CI)**           **P-value**
                                                                                                                           
  Age (≥45 years old vs. \<45 years old)   3.696 (0.768--17.796)     0.103                       0.204 (0.003--16.021)     0.475
  Sex (male vs. female)                    1.661(0.345--7.995)       0.527                                                 
  BMI (≥25 kg/m2 vs. \<25 kg/m2)           3.533 (0.734--17.010)     0.115                                                 
  Tumor size (\>2 cm vs. ≤2 cm)            10.131 (2.103--48.810)    **0.004**                   1.949 (0.160--23.801)     0.601
  Capsule invasion (yes vs. no)            8.522 (1.1066--68.143)    **0.043**                   2.477 (0.171--35.817)     0.506
  Multifocality (yes vs. no)               3.401 (0.850--13.600)     0.084                                                 
  CLNM (yes vs. no)                        6.338 (1.316--30.521)     **0.021**                   0.434 (0.048--3.939)      0.458
  LLNM (yes vs. no)                        17.896 (3.709--86.335)    **\<0.001**                 3.484 (0.461--26.302)     0.226
  Extrathyroidal invasion (yes vs. no)     5.814 (1.453--23.265)     **0.013**                   0.738 (0.092--5.944)      0.775
  Vascular invasion (yes vs. no)           16.064 (3.985--64.746)    **\<0.001**                 17.258 (2.434--122.345)   **0.004**
  Distant metastasis (yes vs. no)          18.993 (3.866--93.306)    **\<0.001**                 3.023 (0.476--14.376)     0.052
  TNM stage (III+IV vs. I+II)              8.492 (1.763--40.902)     **0.008**                   3.542 (0.428--29.316)     0.241
  MMP-9 score (≥8 points vs. \<8 points)   10.471 (2.173--50.450)    **0.003**                   15.329 (1.368--171.717)   **0.027**

BMI, body mass index; CLNM, central lymph node metastasis; LLNM, lateral lymph node metastasis; PTC, papillary thyroid carcinoma; SPRD, structurally persistent disease/recurrent disease; TNM, tumor-node-metastasis. Bold indicates a significant difference. The Univariate Cox proportional hazard analysis was conducted to determine the risks of disease status and SPRD. Variables with significance (P\<0.05) in univariate analyses were entered into the multivariable phase.
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